Prospective Registry of EoSinophilic esOphagitis

Key facts

Sponsor

IRCCS San Raffaele

Intervention

Eosinophilic Esophagitis(other)

Enrollment

1000 enrolled

Eligibility

All sexes

Timeline

2024 – 2044

Study locations (1)

• IRCCS San Raffaele, Milan, Lombardy, Italy

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for NON RARE IN EUROPE: Eosinophilic esophagitis

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT07112378
  A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis
  Regeneron Pharmaceuticals
• RECRUITINGNCT07156357
  Surface EMG Testing on Swallowing in EoE Patients
  Mayo Clinic
• RECRUITINGNCT07012928
  Local Clinical and Immunological Responses in Eosinophilic Esophagitis (EoE) Patients, Role of Mucosal Barrier Function and Type II Inflammation
  Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
• RECRUITINGNCT06972147
  Prevalence and Description of FIRE (Food Induced Immediate Response of the Esophagus) in the Pediatric Population With Eosinophilic Esophagitis
  University Hospital, Angers
• RECRUITINGPHASE2NCT05485155
  Zemaira Eosinophilic Esophagitis Pilot Study
  Children's Hospital Medical Center, Cincinnati
• ENROLLING BY INVITATIONNANCT06756581
  Tolerability of Baked Dairy Protein in Eosinophilic Esophagitis Patients With Cow Milk Protein Trigger
  Shaare Zedek Medical Center
• RECRUITINGPHASE2NCT06705387
  Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE
  University of Colorado, Denver
• RECRUITINGNCT06693531
  A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
  Regeneron Pharmaceuticals

See all trials for NON RARE IN EUROPE: Eosinophilic esophagitis →